JP2014517836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517836A5 JP2014517836A5 JP2014510511A JP2014510511A JP2014517836A5 JP 2014517836 A5 JP2014517836 A5 JP 2014517836A5 JP 2014510511 A JP2014510511 A JP 2014510511A JP 2014510511 A JP2014510511 A JP 2014510511A JP 2014517836 A5 JP2014517836 A5 JP 2014517836A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound
- alkyl
- moiety
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 155
- 238000000034 method Methods 0.000 claims description 85
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 229910052799 carbon Inorganic materials 0.000 claims description 43
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 24
- -1 -OH Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 239000012069 chiral reagent Substances 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 11
- 229940002612 prodrug Drugs 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 230000008484 agonism Effects 0.000 claims description 5
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 0 CC(C)*Oc(c(C#N)c1)ccc1-c1cnc(-c2c(CCC3N)c3ccc2)[s]1 Chemical compound CC(C)*Oc(c(C#N)c1)ccc1-c1cnc(-c2c(CCC3N)c3ccc2)[s]1 0.000 description 16
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 13
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 13
- 231100001274 therapeutic index Toxicity 0.000 description 8
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
- 239000000556 agonist Substances 0.000 description 5
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical group CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- JRCCMJGRDJTQNS-UHFFFAOYSA-N 1-azido-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2C(N=[N+]=[N-])CCCC2=C1 JRCCMJGRDJTQNS-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- ARXZAIZCRNOWGB-UHFFFAOYSA-N CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CCC3)c3ccc2)[s]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CCC3)c3ccc2)[s]1 ARXZAIZCRNOWGB-UHFFFAOYSA-N 0.000 description 2
- IJTATBVIZVMQBT-UHFFFAOYSA-N CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CCC3NCCS=O)c3ccc2)[s]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CCC3NCCS=O)c3ccc2)[s]1 IJTATBVIZVMQBT-UHFFFAOYSA-N 0.000 description 2
- FFUBFQCTDBXZMZ-DEOSSOPVSA-N CC(C)Oc(ccc(-c1ncc(-c2cccc3c2CC[C@@H]3NCC(N2CCCC2)=O)[s]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1ncc(-c2cccc3c2CC[C@@H]3NCC(N2CCCC2)=O)[s]1)c1)c1C#N FFUBFQCTDBXZMZ-DEOSSOPVSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DQBCRVIBTFHJLM-UHFFFAOYSA-N 2-bromo-1,3,4-thiadiazole Chemical class BrC1=NN=CS1 DQBCRVIBTFHJLM-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- XSZVUKXQDQTDQT-QFIPXVFZSA-N CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CC[C@@H]3NCC(N(C)C)=O)c3ccc2)[s]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CC[C@@H]3NCC(N(C)C)=O)c3ccc2)[s]1 XSZVUKXQDQTDQT-QFIPXVFZSA-N 0.000 description 1
- DBFLEUHKDHLJTP-QFIPXVFZSA-N CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CC[C@@H]3NCCOC)c3ccc2)[s]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1ncc(-c2c(CC[C@@H]3NCCOC)c3ccc2)[s]1 DBFLEUHKDHLJTP-QFIPXVFZSA-N 0.000 description 1
- FIRVFYZVZCHDSX-NRFANRHFSA-N CC(C)Oc(c(C#N)c1)ccc1-c1nnc(-c2cccc3c2CCC[C@@H]3NCC(NC)=O)[s]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1nnc(-c2cccc3c2CCC[C@@H]3NCC(NC)=O)[s]1 FIRVFYZVZCHDSX-NRFANRHFSA-N 0.000 description 1
- MQUHXLNCCTZXSJ-NRFANRHFSA-N CC(C)Oc(c(N)c1)ccc1-c1nnc(-c2c(CCC[C@@H]3NS(CCOC)(=O)=O)c3ccc2)[s]1 Chemical compound CC(C)Oc(c(N)c1)ccc1-c1nnc(-c2c(CCC[C@@H]3NS(CCOC)(=O)=O)c3ccc2)[s]1 MQUHXLNCCTZXSJ-NRFANRHFSA-N 0.000 description 1
- IRCFTXRTDROOIZ-UHFFFAOYSA-N CC(C)Oc(cc1)c(C)cc1-c1ncc(-c2c(CCC3N4CCCCC4)c3ccc2)[s]1 Chemical compound CC(C)Oc(cc1)c(C)cc1-c1ncc(-c2c(CCC3N4CCCCC4)c3ccc2)[s]1 IRCFTXRTDROOIZ-UHFFFAOYSA-N 0.000 description 1
- HAADVQLQVHKMRH-UHFFFAOYSA-N CC(C)Oc(ccc(-c1ccc(-c2cccc3c2CCC3O)[s]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1ccc(-c2cccc3c2CCC3O)[s]1)c1)c1C#N HAADVQLQVHKMRH-UHFFFAOYSA-N 0.000 description 1
- LGTCIBWMSCRNLV-HSTJUUNISA-N CC(C)Oc(ccc(-c1ncc(-c2c(CCC3N(CC4)C[C@H]4O)c3ccc2)[s]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1ncc(-c2c(CCC3N(CC4)C[C@H]4O)c3ccc2)[s]1)c1)c1C#N LGTCIBWMSCRNLV-HSTJUUNISA-N 0.000 description 1
- DBFLEUHKDHLJTP-UHFFFAOYSA-N CC(C)Oc(ccc(-c1ncc(-c2c(CCC3NCCOC)c3ccc2)[s]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1ncc(-c2c(CCC3NCCOC)c3ccc2)[s]1)c1)c1C#N DBFLEUHKDHLJTP-UHFFFAOYSA-N 0.000 description 1
- PDHJOJDTKNNIAL-FQEVSTJZSA-N CC(C)Oc(ccc(-c1ncc(-c2c(CC[C@@H]3NCC(O)=O)c3ccc2)[s]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1ncc(-c2c(CC[C@@H]3NCC(O)=O)c3ccc2)[s]1)c1)c1C#N PDHJOJDTKNNIAL-FQEVSTJZSA-N 0.000 description 1
- ZNINXPXWDFBZBP-NRFANRHFSA-N CC(C)Oc(ccc(-c1ncc(-c2c(CC[C@@H]3NCCO)c3ccc2)[s]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1ncc(-c2c(CC[C@@H]3NCCO)c3ccc2)[s]1)c1)c1C#N ZNINXPXWDFBZBP-NRFANRHFSA-N 0.000 description 1
- ZESMVJNMKLWJNE-XESZBRCGSA-N CC(C)Oc(ccc(-c1ncc(-c2cccc3c2CCC3N[C@H](C)CO)[s]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1ncc(-c2cccc3c2CCC3N[C@H](C)CO)[s]1)c1)c1C#N ZESMVJNMKLWJNE-XESZBRCGSA-N 0.000 description 1
- ZGCWDFFYOAEJAQ-HXUWFJFHSA-N CC(C)Oc(ccc(-c1nnc(-c2cccc3c2CCC[C@H]3NCCN=S)[s]1)c1)c1NC Chemical compound CC(C)Oc(ccc(-c1nnc(-c2cccc3c2CCC[C@H]3NCCN=S)[s]1)c1)c1NC ZGCWDFFYOAEJAQ-HXUWFJFHSA-N 0.000 description 1
- ZPRQXGPGMPRXHF-PKAZHMFMSA-N CC(C)Oc(ccc(C(S/C(/c1c(CCC2N3CCCC3)c2ccc1)=C\N)=C)c1)c1C#N Chemical compound CC(C)Oc(ccc(C(S/C(/c1c(CCC2N3CCCC3)c2ccc1)=C\N)=C)c1)c1C#N ZPRQXGPGMPRXHF-PKAZHMFMSA-N 0.000 description 1
- NXVMHQBGEDYGMA-UHFFFAOYSA-N CCSCCNC(CCC12)C1=CC=CC2c1cnc(-c(cc2C#N)ccc2OC(C)C)[s]1 Chemical compound CCSCCNC(CCC12)C1=CC=CC2c1cnc(-c(cc2C#N)ccc2OC(C)C)[s]1 NXVMHQBGEDYGMA-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FCFUVRKPBYUYOI-UHFFFAOYSA-N NCC(N(CC1)CC1O)=O Chemical compound NCC(N(CC1)CC1O)=O FCFUVRKPBYUYOI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical group CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000004867 thiadiazoles Chemical group 0.000 description 1
- GOWNSHUNTJWVOM-UHFFFAOYSA-N tributyl(1,3-thiazol-5-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CS1 GOWNSHUNTJWVOM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486184P | 2011-05-13 | 2011-05-13 | |
| US61/486,184 | 2011-05-13 | ||
| PCT/US2012/037609 WO2012158550A2 (en) | 2011-05-13 | 2012-05-11 | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517836A JP2014517836A (ja) | 2014-07-24 |
| JP2014517836A5 true JP2014517836A5 (enExample) | 2015-06-25 |
| JP6129159B2 JP6129159B2 (ja) | 2017-05-17 |
Family
ID=47177578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510511A Active JP6129159B2 (ja) | 2011-05-13 | 2012-05-11 | 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9481659B2 (enExample) |
| EP (1) | EP2706999B1 (enExample) |
| JP (1) | JP6129159B2 (enExample) |
| ES (1) | ES2758841T3 (enExample) |
| WO (1) | WO2012158550A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012005560A (es) | 2009-11-13 | 2012-10-05 | Receptos Inc | Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral. |
| US9115054B2 (en) | 2013-02-21 | 2015-08-25 | Bristol-Myers Squibb Company | Tetrahydronaphthalenyl compounds useful as sipi agonists |
| CN106187945A (zh) * | 2016-07-22 | 2016-12-07 | 辽宁师范大学 | 一种有机合成中间体的合成方法 |
| ES2877686T3 (es) * | 2016-07-22 | 2021-11-17 | Shijiazhuang Sagacity New Drug Dev Co Ltd | Agonista S1P1 y aplicación del mismo |
| CN110325517B (zh) * | 2017-02-28 | 2021-03-02 | 南京明德新药研发有限公司 | 螺环类化合物及其应用 |
| EP3849965A1 (en) * | 2018-09-12 | 2021-07-21 | Pharmazell GmbH | A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile |
| CN112457305B (zh) | 2019-09-09 | 2025-01-10 | 上海长森药业有限公司 | 含三环结构的芳香杂环化合物，及其制备方法和应用 |
| US11760751B2 (en) | 2020-03-04 | 2023-09-19 | Helioeast Science & Technology Co., Ltd. | Benzo 2-azaspiro[4.4]nonane compound and use thereof |
| EP4151634A4 (en) | 2020-05-11 | 2024-08-21 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | PREPARATION OF A BIARYL RING-LINKED AROMATIC HETEROCYCLIC DERIVATIVE AS AN IMMUNOMODULATOR AND ITS USE |
| WO2022213935A1 (zh) * | 2021-04-09 | 2022-10-13 | 南昌弘益药业有限公司 | 噁二唑取代的螺环类化合物及其应用 |
| CN117164415B (zh) * | 2023-07-24 | 2024-08-02 | 湖北航天化学技术研究所 | 一种硼酸酯型含氟燃烧促进剂及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| EP0583346A1 (en) | 1991-04-12 | 1994-02-23 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| PT1057827E (pt) | 1998-01-23 | 2003-11-28 | Sankyo Co | Derivados da espiropiperidina |
| US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| DE60335827D1 (de) * | 2002-12-20 | 2011-03-03 | Merck Sharp & Dohme | 1-(amino)indane als edg-rezeptoragonisten |
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| WO2004094413A1 (en) * | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | Phenacyl 2-hydroxy-3-diaminoalkanes |
| US20070043014A1 (en) | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| EP1697333A4 (en) * | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| EP1851188A1 (en) | 2005-02-22 | 2007-11-07 | Teva Pharmaceutical Industries Limited | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| EP1924546A1 (en) * | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| CA2634488C (en) | 2005-12-21 | 2016-10-04 | Joseph Gabriele | Catecholamine regulated protein |
| CA2643055A1 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| US20080009534A1 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| CA2669104A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
| AU2007343139A1 (en) * | 2006-12-21 | 2008-07-17 | Pfizer Products Inc. | Compounds having both angiotensin II receptor antagonism and PPARy activating activities |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| WO2008106204A1 (en) | 2007-02-28 | 2008-09-04 | Rib-X-Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| WO2009048474A1 (en) * | 2007-10-12 | 2009-04-16 | Pharmacopeia, Inc. | 2,7,9-substituted purinone derivatives for immunosuppression |
| WO2009131090A1 (ja) * | 2008-04-21 | 2009-10-29 | 旭化成ファーマ株式会社 | アミノ酸化合物 |
| EP3782991A1 (en) | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| US20100249071A1 (en) * | 2009-03-30 | 2010-09-30 | Exelixis, Inc. | Modulators of S1P and Methods of Making And Using |
| GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| GB0911130D0 (en) | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
| ES2665461T3 (es) | 2009-11-13 | 2018-04-25 | Celgene International Ii Sàrl | Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral |
| MX2012005560A (es) | 2009-11-13 | 2012-10-05 | Receptos Inc | Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral. |
| PH12012500940B1 (en) | 2009-11-13 | 2018-09-26 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| CA2851525A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2012
- 2012-05-11 US US14/117,514 patent/US9481659B2/en active Active
- 2012-05-11 JP JP2014510511A patent/JP6129159B2/ja active Active
- 2012-05-11 WO PCT/US2012/037609 patent/WO2012158550A2/en not_active Ceased
- 2012-05-11 EP EP12785231.7A patent/EP2706999B1/en active Active
- 2012-05-11 ES ES12785231T patent/ES2758841T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014517836A5 (enExample) | ||
| AU2022201688B2 (en) | Compounds as nuclear transport modulators and uses thereof | |
| JP2013510884A5 (enExample) | ||
| AU2009304598B2 (en) | S1P receptors modulators and their use thereof | |
| US10968202B2 (en) | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | |
| TWI837169B (zh) | 甲狀腺素受體β促效劑化合物 | |
| ES2675799T3 (es) | Moduladores selectivos del receptor esfingosina 1-fosfato heterocíclica | |
| JP6129159B2 (ja) | 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター | |
| WO2018170173A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| JP2013510883A5 (enExample) | ||
| MXPA02001597A (es) | Derivados del acido benzoico para el tratamiento de diabetes mellitus. | |
| CA2918284A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| TW200524603A (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| JP2011504903A5 (enExample) | ||
| JP2017519754A5 (enExample) | ||
| JP2020534264A (ja) | ベータ−ヒドロキシ複素環アミンおよび高血糖症の治療におけるそれらの使用 | |
| JP2019510082A (ja) | 高血糖症の治療のための化合物 | |
| JP2011504504A (ja) | 肺および心血管障害を治療するための置換されたベンゾ・アゾールｐｄｅ４抑制剤 | |
| JP2019520344A5 (enExample) | ||
| TW200427689A (en) | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists | |
| CN102186824B (zh) | 稠环衍生物及其医药用途 | |
| WO2017146246A1 (ja) | ピペリジン誘導体 | |
| JP6466465B2 (ja) | オレキシン受容体拮抗薬としての置換シクロペンタン、テトラヒドロフラン、及びピロリジン | |
| WO2020081689A1 (en) | Azaindole inhibitors of wild-type and mutant forms of lrrk2 | |
| US8772304B2 (en) | Benzimidazole inhibitors of leukotriene production |